New vaccines against tuberculosis

Tropical Medicine and International Health

Volumn 9, Issue 7, 2004, Pages 818-826

  Doherty, T Mark ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

Africa; Clinical trials; Novel vaccines; Recommendations; Tuberculosis

Indexed keywords

72 F; 72 F VACCINE; ADJUVANT; AG 85 B VACCINE; ANTIGEN; BCG VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; ESAT 6; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOSTIMULATING AGENT; MONOPHOSPHORYL PHOSPHOLIPID A; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR;

DISEASE CONTROL; TUBERCULOSIS; VACCINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; BCG VACCINATION; CELL POPULATION; CELLULAR IMMUNITY; CHEMOTHERAPY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENDEMIC DISEASE; FINANCIAL MANAGEMENT; GENE EXPRESSION; HEALTH PROGRAM; HIGH RISK POPULATION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFECTION; MOLECULAR RECOGNITION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RECOMBINANT GENE; T LYMPHOCYTE; TH1 CELL; TUBERCULOSIS; VACCINIA VIRUS; VIRULENCE;

ANIMALS; BCG VACCINE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; MYCOBACTERIUM TUBERCULOSIS; POVERTY; RISK FACTORS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM TUBERCULOSIS; PRIMATES; VACCINIA VIRUS;

EID: 3242657063     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01275.x     Document Type: Conference Paper

References (69)

1. Acheson D, Alleyne GA, Casas JA et al. (2000) Round table discussion. Health inequalities and the health of the poor. Bulletin of the World Health Organization 78, 75-85.
2. Agger EM & Andersen P (2001) Tuberculosis subunit vaccine development: on the role of interferon-gamma. Vaccine 19, 2298-2302.
3. Andersen P, Munk ME Pollock JM & TM Doherty (2000) Specific immune-based diagnosis of tuberculosis. Lancet 356, 1099-1104.
4. Anon. (2001a) Global Tuberculosis Control. WHO Report 2001. World Health Organization, Geneva, Switzerland, pp. 181.
5. Anon. (2001b) Tuberculosis vaccine trials set to begin in Britain, vol. 2001. Reuters Limited, London.
6. Behr MA & Small PM (1997) Has BCG attenuated to impotence? Nature 389, 133-134.
7. Boom WH (1996) The role of T-cell subsets in Mycobacterium tuberculosis infection. Infectious Agents and Disease 5, 73-81.
8. Brandt L, Elhay M, Rosenkrands I, Lindblad EB & Andersen P (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infection and Immunity 68, 791-795.
9. Brandt L, Feino Cunha J, Weinreich Olsen A et al. (2002) Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infection and Immunity 70, 672-678.
10. Brooks JV, Frank AA, Keen MA, Bellisle JT & Orme IM (2001) Boosting vaccine for tuberculosis. Infection and Immunity 69, 2714-2717.
11. Buddle BM, Wedlock DN, Parlane NA, Corner LA, De Lisle GW & Skinner MA (2003) Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infection and Immunity 71, 6411-6419.
12. Campos JM, Simonetti JP, Pone MV, Carvalho LA, Pereira AC & Garrido JR (1996) Disseminated Bacillus Calmette-Guerin infection in HIV-infected children: case report and review. Pediatric AIDS and HIV Infection 7, 429-432.
13. Canaday DH, Wilkinson RJ, Li Q, Harding CV, Silver RF & Boom WH (2001) CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. Journal of Immunology 167, 2734-2742.
14. Chackerian AA, Perera TV & Behar SM (2001) Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Infection and Immunity 69, 2666-2674.
15. Colditz GA, Berkey CS, Mosteller F et al. (1995) The efficacy of Bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96 (1 Pt 1), 29-35.
16. Collins HL & Kaufmann SH (2001) Prospects for better tuberculosis vaccines. The Lancet Infectious Disease 1, 21-28.
17. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG & Orme IM (1993) Disseminated tuberculosis in interferon gamma gene-disrupted mice. Journal of Experimental Medicine 178, 2243-2247.
18. da Fonseca DP, Frerichs J, Singh M, Snippe H & Verheul AF (2000) Induction of antibody and T-cell responses by immunization with ISCOMS containing the 38-kilodalton protein of Mycobacterium tuberculosis. Vaccine 19, 122-131.
19. de Boer AS & van Soolingen D (2000) Recurrent tuberculosis due to exogenous reinfection. New England Journal of Medicine 342, 1050-1051.
20. de Bruyn G & Garner P (2003) Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database of Systematic Reviews, CD001166.
21. De Groot AS, Bosma A, Chinai N et al. (2001) From genome to vaccine:in silico predictions, ex vivo verification. Vaccine 19, 4385-4395.
22. Denis O, Tanghe A, Palfliet K et al. (1998) Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infection and Immunity 66, 1527-1533.
23. Dietrich G, Viret JF & Hess J (2003) Mycobacterium bovis BCG-based vaccines against tuberculosis: novel developments. Vaccine 21, 667-670.
24. Doherty TM, Olsen AW, van Pinxteren L & Andersen P (2002a) Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infection and Immunity 70, 3111-3121.
25. Doherty TM, Demissie A, Olobo J et al. (2002b) Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. Journal of Clinical Microbiology 40, 704-706.
26. Dorman SE & Holland SM (2000) Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine and Growth Factor Reviews 11, 321-333.
27. Dye C, Watt CJ & Bleed D (2002) Low access to a highly effective therapy: a challenge for international tuberculosis control. Bulletin of the World Health Organization 80, 437-444.
28. Dye C, Watt CJ, Bleed DM & Williams BG (2003) What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinburg) 83, 35-43.
29. Feng CG, Palendira U, Demangel C, Spratt JM, Malin AS & Britton WJ (2001) Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infection and Immunity 69, 4174-4176.
30. Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339-1345.
31. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA & Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. Journal of Experimental Medicine 178, 2249-2254.
32. Horwitz MA, Harth G, Dillon BJ & Maslesa-Galic S (2000) Recombinant Bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proceedings of the National Academy of Sciences of the United States of America 97, 13853-13858.
33. Keet DF, Kriek NP, Bengis RG, Grobler DG & Michel A (2000) The rise and fall of tuberculosis in a free-ranging chacma baboon troop in the Kruger National Park. Onderstepoort Journal of Veterinary Research 67, 115-122.
34. Lalvani A, Nagvenkar P, Udwadia Z et al. (2001a) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. Journal of Infectious Diseases 183, 469-477.
35. Lalvani A, Pathan AA, McShane H et al. (2001b) Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. American Journal of Respiratory and Critical Care Medicine 163, 824-828.
36. Langermans JA, Andersen P, van Soolingen D et al. (2001) Divergent effect of Bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research. Proceedings of the National Academy of Sciences of the United States of America 98, 11497-11502.
37. Leung CC, Tam CM, Chan SL, Chan-Yeung M, Chan CK & Chang KC (2001) Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. The International Journal of Tuberculosis and Lung Disease 5, 717-723.
38. Lima KM, Bonato VL, Faccioli LH et al. (2001) Comparison of different delivery systems of vaccination for the induction of protection against tuberculosis in mice. Vaccine 19, 3518-3525.
39. Lowrie DB, Tascon RE, Bonato VL et al. (1999) Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269-271.
40. McMurray DN (2001) Disease model: pulmonary tuberculosis. Trends in Molecular Medicine 7, 135-137.
41. McMurray DN (2003) Recent progress in the development and testing of vaccines against human tuberculosis. International Journal for Parasitology 33, 547-554.
42. McShane H, Brookes R, Gilbert SC & Hill AV (2001) Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infection and Immunity 69, 681-686.
43. Mittal SK, Aggarwal V, Rastogi A & Saini N (1996) Does B.C.G. vaccination prevent or postpone the occurrence of tuberculous meningitis? Indian Journal of Pediatrics 63, 659-664.
44. Mollenkopf H, Dietrich G & Kaufmann SH (2001) Intracellular bacteria as targets and carriers for vaccination. Biological Chemistry 382, 521-532.
45. Munk ME & Emoto M (1995) Functions of T-cell subsets and cytokines in mycobacterial infections. European Respiratory Journal. Supplement 20, 668s-675s.
46. Nunn P (2001) The global control of tuberculosis: what are the prospects? Scandinavian Journal of Infectious Diseases 33, 329-332.
47. Okkels LM, Doherty TM & Andersen P (2003) Selecting the components for a safe and efficient tuberculosis subunit vaccine-recent progress and post-genomic insights. Current Pharmaceutical Biotechnology 4, 69-83.
48. Orme IM (1987) The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. Journal of Immunology 138, 293-298.
49. Peppoloni S, Ruggiero P, Contorni M et al. (2003) Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Review of Vaccines 2, 285-293.
50. Pym AS, Brodin P, Majlessi L et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Medicine 9, 533-539.
51. Ravn P, Demissie A, Eguale T et al. (1999) Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. Journal of Infectious Diseases 179, 637-645.
52. Reed SG, Alderson MR, Dalemans W, Lobet Y & Skeiky YA (2003) Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinburg) 83, 213-219.
53. Seah GT & Rook GA (2001) High levels of mRNA encoding IL-4 in unstimulated peripheral blood mononuclear cells from tuberculosis patients revealed by quantitative nested reverse transcriptase-polymerase chain reaction; correlations with serum IgE levels. Scandinavian Journal of Infectious Diseases 33, 106-109.
54. Serbina NV & Flynn JL (2001) CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infection and Immunity 69, 4320-4328.
55. Silva CL, Bonato VL, Lima VM, Faccioli LH & Leao SC (1999) Characterization of the memory/activated T cells that mediate the long- lived host response against tuberculosis after Bacillus Calmette-Guerin or DNA vaccination. Immunology 97, 573-581.
56. Smith D, Wiegeshaus E & Balasubramanian V (2000) An analysis of some hypotheses related to the Chingelput Bacille Calmette-Guerin trial. Clinical Infectious Diseases 31(Suppl 3), S77-S80.
57. Smith DA, Parish T, Stoker NG & Bancroft GJ (2001) Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infection and Immunity 69, 1142-1150.
58. Stenger S (2001) Cytolytic T cells in the immune response to Mycobacterium tuberculosis. Scandinavian Journal of Infectious Diseases 33, 483-487.
59. Sterne JA, Rodrigues LC & Guedes IN (1998) Does the efficacy of BCG decline with time since vaccination? The International Journal of Tuberculosis and Lung Disease 2, 200-207.
60. Suarez PG, Watt CJ, Alarcon E et al. (2001) The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. Journal of Infectious Diseases 184, 473-478.
61. Tala-Heikkila MM, Tuominen JE & Tala EO (1998) Bacillus Calmette-Guerin revaccination questionable with low tuberculosis incidence. American Journal of Respiratory and Critical Care Medicine 157 (4 Pt 1), 1324-1327.
62. Tanghe A, D'Souza S, Rosseels V et al. (2001) Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infection and Immunity 69, 3041-3047.
63. Turner J, D'Souza CD, Pearl JE et al. (2001) CD7- and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis. American Journal of Respiratory Cell and Molecular Biology 24, 203-209.
64. Turner OC, Roberts AD, Frank AA et al. (2000) Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis. Infection and Immunity 68, 3674-3679.
65. Ulrich JT & Myers KR (1995) Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharmaceutical Biotechnology 6, 495-524.
66. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM & Andersen P (2000) Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. European Journal of Immunology 30, 3689-3698.
67. Vekemans J, Lienhardt C, Sillah JS et al. (2001) Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infection and Immunity 69, 6554-6557.
68. Walsh GP, Tan EV, dela Cruz EC et al. (1996) The Philippine cynomolgus monkey (Macaca fasicularis) provides a new non-human primate model of tuberculosis that resembles human disease. Nature Medicine 2, 430-436.
69. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P & Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infection and Immunity 69, 2773-2778.